EnGene Executives Bulk Buy Shares in Coordinated Move, Betting on 2026 Biologics License Application Despite Losses
EnGene insiders’ bulk option buys signal confidence in a 2026 BLA push, boosting stock sentiment while cautioning investors on current losses.
3 minutes to read